Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020.
   Google Scholar
• Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int. 2014;111(50):847–855. doi:10.3238/arztebl.2014.0847
   PubMed Web of Science ®Google Scholar
• Nagasaki T, Sato K, Kume N, et al. The prevalence and disease burden of severe eosinophilic asthma in Japan. J Asthma. 2019;56(11):1147–1158. doi:10.1080/02770903.2018.1534967
   PubMed Web of Science ®Google Scholar
• Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37–42. doi:10.1016/j.anai.2015.10.027
   PubMed Web of Science ®Google Scholar
• Albers FC, Price RG, Smith SG, Yancey SW. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J Allergy Clin Immunol. 2017;140(5):1464–1466.e4. doi:10.1016/j.jaci.2017.06.010
   Web of Science ®Google Scholar
• Domingo C. Overlapping effects of new monoclonal antibodies for severe asthma. Drugs. 2017;77(16):1769–1787. doi:10.1007/s40265-017-0810-5
   PubMed Web of Science ®Google Scholar
• Landi C, Cameli P, Vantaggiato L, et al. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab. Biochim Biophys Acta Proteins Proteom. 2021;1869(2):140563. doi:10.1016/j.bbapap.2020.140563
   Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861. doi:10.18553/jmcp.2016.22.7.848
   PubMedGoogle Scholar
• Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124. doi:10.1136/thoraxjnl-2017-210531
   PubMed Web of Science ®Google Scholar
• Brightling CE, Gupta S, Gonem S, Siddiqui S. Lung damage and airway remodelling in severe asthma. Clin Exp Allergy. 2012;42(5):638–649. doi:10.1111/j.1365-2222.2011.03917.x
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975–991. doi:10.1016/j.immuni.2019.03.018
   PubMed Web of Science ®Google Scholar
• Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018;52(5):1801393. doi:10.1183/13993003.01393-2018
   PubMed Web of Science ®Google Scholar
• Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138. doi:10.1111/cea.12853
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20. doi:10.1016/j.jaci.2018.08.031
   PubMed Web of Science ®Google Scholar
• Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. doi:10.1080/20018525.2018.1536097
   PubMed Web of Science ®Google Scholar
• Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M. Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1):122–130.e1. doi:10.1016/j.jaip.2018.08.036
   PubMed Web of Science ®Google Scholar
• Mauger D, Apter AJ. Indirect treatment comparisons and biologics. J Allergy Clin Immunol. 2019;143(1):84–86. doi:10.1016/j.jaci.2018.11.005
   Web of Science ®Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008
   PubMed Web of Science ®Google Scholar
• Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006;15(100):61–67. doi:10.1183/09059180.00010002
   Google Scholar
• Cameli P, Bergantini L, d’Alessandro M, et al. A comprehensive evaluation of mepolizumab effectiveness in a real-life setting. Int Arch Allergy Immunol. 2020;181(8):606–612. doi:10.1159/000507996
   PubMed Web of Science ®Google Scholar
• Bergantini L, d’Alessandro M, Cameli P, et al. Personalized approach of severe eosinophilic asthma patients treated with mepolizumab and benralizumab. Int Arch Allergy Immunol. 2020;181(10):746–753. doi:10.1159/000508936
   Web of Science ®Google Scholar
• Vantaggiato L, Perruzza M, Refini RM, et al. Mepolizumab and benralizumab in severe eosinophilic asthma: preliminary results of a proteomic study. Lung. 2020;198(5):761–765. doi:10.1007/s00408-020-00379-6
   PubMed Web of Science ®Google Scholar
• Bergantini L, d’Alessandro M, Cameli P, et al. Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scand J Immunol. 2021;94:e13031. doi:10.1111/sji.13031
   PubMed Web of Science ®Google Scholar
• Korn S, Both J, Jung M, Hübner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011;107(6):474–479. doi:10.1016/j.anai.2011.09.001
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Raphiou I, Zeiger RS, Stempel D, Kral K, Pascoe S. Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies. ERJ Open Res. 2019;5(2):00153–2018. doi:10.1183/23120541.00153-2018
   PubMedGoogle Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-5
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Korn S, Mathur SK, et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020;43(5):409–425. doi:10.1007/s40264-020-00926-3
   PubMed Web of Science ®Google Scholar